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Edited by Veli-Pekka LehtoAbstract The placenta comprises a highly specialized tropho-
blast layer, which arises from the embryo and diﬀerentiates dur-
ing embryonic development to perform specialized functions,
e.g., synthesis of pregnancy-associated hormones, growth factors
and cytokines. As there is no evidence of maternal acute-phase
protein transplacental transfer and trophoblast plays an impor-
tant role in regulating immune responses at the feto-maternal
interface, the expression of acute-phase serum amyloid A (A-
SAA) was investigated in human ﬁrst trimester trophoblast and
trophoblast-like JAR and Jeg-3 choriocarcinoma cells. We here
show expression of cytokine receptors and cytokine-dependent
induction of A-SAA in JAR and Jeg-3 cells. While interleukin-
1a/b is a major agonist for A-SAA expression in JAR, tumor
necrosis factor-a is the predominant agonist in Jeg-3. First tri-
mester trophoblast and JAR/Jeg-3 cells further express the hu-
man homolog of SAA-activating factor-1, a transcription
factor involved in cytokine-mediated induction of A-SAA genes.
A-SAA1 and A-SAA2 transcripts were increased in ﬁrst trimes-
ter trophoblast during pregnancy weeks 10 and 12 suggesting
that A-SAA plays a role during early fetal development.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Acute-phase SAA; Apolipoprotein; Cytokine;
Inﬂammation; Fetal development1. Introduction
Serum amyloid A (SAA), one of the major acute-phase pro-
teins in mammals, is synthesized mostly in the liver. SAA is a
generic term for a family of apolipoproteins coded for by dif-
ferent genes with a high allelic variation and a high degree of
homology between species [1,2]. In humans, the SAA gene
family consists of three genes (SAA1, SAA2, and SAA4) and
a (pseudo)gene (SAA3) [3], all clustered on the short arm of
the chromosome 11. SAA1 and SAA2 genes, so called acute-
phase (A-SAA) genes (with a 96% sequence homology), encode
for SAA1 (the most abundant isoform) and SAA2 protein. Be-
sides a variety of diﬀerent activities and biological properties,*Corresponding author. Fax: +43 316 380 9615.
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doi:10.1016/j.febslet.2005.11.067three major functions have been ascribed to A-SAA protein
[1,2]. (i) Chronically elevated A-SAA concentrations are a pre-
requisite for the pathogenesis of secondary reactive amyloido-
sis [4]. (ii) As concentrations of acute-phase reactants might
correlate with the amount of damaged tissue, measurements
of A-SAA are of value in the assessment of the activity and re-
sponse to therapy during several inﬂammatory diseases [5]. (iii)
A-SAA associates rapidly with high-density lipoproteins dur-
ing the acute-phase thereby impairing the anti-atherogenic
properties of its physiological carrier, i.e., acute-phase high-
density lipoproteins, during inﬂammation [6].
During placental development, trophoblast cells develop
along a cell lineage forming the villous cytotrophoblast with
the overlaying syncytiotrophoblast [7]. Trophoblast cells medi-
ate the contact between two genetically diﬀerent individuals,
the embryo and the mother, by establishing a transient embry-
onic organ, the placenta [7]. Trophoblast cells are of consider-
able interest to investigators attempting to understand the
nature of the apparently privileged immunologic status of
the developing fetus [8]. Normal pregnancy is a state of mild
systemic inﬂammation, where, in addition to their traditional
roles as mediators of inﬂammation, cytokines derived from
placenta and extraplacental membranes appear to be impli-
cated in various aspects of implantation and placental develop-
ment. Apart from their involvement in normal pregnancy,
cytokines may cause adverse eﬀects, leading to intrauterine
infection. Imbalances in the intrauterine cytokine milieu
around the time of implantation and invasion may further play
a causative role in disorders associated with early pregnancy
failure, and are also associated with the abnormal trophoblast
development seen in gestational trophoblastic disease [8].
Recent observations show that A-SAA biosynthesis is not
exclusively limited to hepatic origin [9]. A-SAA is also present
in human placenta [9,10] although no evidence of transplacen-
tal transfer of maternal A-SAA to fetal tissue exists [11]. We
here follow cytokine-mediated A-SAA expression in two hu-
man choriocarcinoma cell lines. Choriocarcinoma cell lines,
replicating trophoblastic cells, derived from the malignant tu-
mor or produced by viral transformation of normal ﬁrst-tri-
mester trophoblast cells, are appropriate systems to mimic
trophoblast behavior in vitro [12–14]. JAR cells share many
of the characteristics of early placental trophoblast cells, such
as synthesis of human chorionic gonadotropin and steroids
[12], and the ability to diﬀerentiate into syncytiotrophoblast-likeblished by Elsevier B.V. All rights reserved.
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gonadotropin and placental lactogen – hallmarks of tropho-
blasts [15] – and form large, multinucleated syncytia in culture
[14] which resemble that of syncytiotrophoblasts in vivo. Fur-
thermore, we were interested whether both fetally derived JAR
and Jeg-3 cells and in utero invasive ﬁrst trimester trophoblast
cells express A-SAA1 and A-SAA2. Finally, we were interested
whether the human homolog of SAA-activating factor-1
(SAF-1), a Cys2His2-type zinc ﬁnger transcription factor is in-
volved in cytokine-induced expression of SAA1 and SAA2 [16].2. Materials and methods
2.1. Cell culture studies
Human choriocarcinoma cells. JAR and Jeg-3 cell lines were main-
tained in Dulbeccos modiﬁed essential medium, supplemented with
10% (v/v) fetal calf serum, and 100 U/ml penicillin/streptomycin at
37 C under 5% CO2 [17].
Human ﬁrst trimester trophoblast. Mononucleated trophoblast cells
were obtained from clinically normal human pregnancies which were
interrupted for psychosocial reasons by vacuum suction and curettage
at weeks 7–12 of gestation (approved by the Ethical Committee at the
Karl-Franzens University Graz). Isolation of ﬁrst trimester trophoblast
was performed exactly as described [18]. The purity of the trophoblast
populationswas assessed by indirect immunoﬂuorescence staining using
the followingmurine monoclonal antibodies for characterization: (i) for
trophoblast cells: anti-cytokeratin, (ii) for ﬁbroblasts: anti-human
vimentin, (iii) for endothelial cells: anti-von Willebrand factor, and (iv)
for peripheral lymphocytes: anti-CD45 antibody [18].
Human hepatoma cells. HUH-7 cells were grown in RPMI-1640
medium (Bio Whitaker, Austria) containing 10% (v/v) fetal calf serum
and L-glutamine under standard conditions (37 C, 5% CO2, 95%
humidity) [19].
Human macrophages. The monocytic THP-1 cell line was maintained
in RPMI 1640 medium supplemented with 2 mM glutamine, 100 U/ml
penicillin, 100 lg/ml streptomycin, and 10% (v/v) fetal calf serum. To
induce diﬀerentiation, THP-1 cells were cultured for 72 h in the pres-
ence of 160 nM phorbol myristate acetate [20].
2.2. Treatment with cytokines, dexamethasone, and butyrate
Choriocarcinoma cells were seeded in 6-well plates (Costar, Austria)
and incubated for up to 24 h in medium containing interleukin-1a (IL-
1a), IL-1b, IL-6, or tumor necrosis factor-a (TNFa) (all 10 ng/ml)Table 1
Description of primers, expected ampliﬁed fragment size, and annealing tem
Gene Accession No. Primers (start position on + strand)
SAA1 F 50 CAG ACA AAT ACT TCC ATG CT 3 0 (373)
NM_000331 R 5 0 ATT GTG TAC CCT CTC CCC 3 0 (658)
SAA2 F 50 CAG ACA AAT ACT TCC ATG CT 3 0 (172)
NM_030754 R 5 0 ATT ATA TGC CAT ATC TCA GC 30 (479)
SAF-1/2 F 50 GCC AGG GTC CTC ACC ATG TCT G 3 0(1407
NM_002383 R 5 0 CAA CTT GGA GCT CAC CAG GG 30 (1577/17
AF489858 a
IL-1R1 F 50 TGC TTA CTG GAA GTG GAA TGG 30 (853)
NM_000877 R 5 0 CCT CAG GCA AGA CTT TAA ACA C 30 (130
IL-1R2 F 50 GCA ATG TTG CGC TTG TAC GTG 30 (227)
NM_004633 R 5 0 GTC TTT ATC CAA AAG AAG AG30 (747)
IL-6R F 50 AGA GGC GTG CTG ACC AGT CTG 30 (531)
NM_000565 R 5 0 ACG GCT CCT GGA AGT CTT CGG 3 0 (910)
TNFR1 F 50 TCG ATT TGC TGT ACC AAG T 3 0 (447)
NM_001065 R 5 0 GAA AAT GAC CAG GGG CAA CAG 3 0 (918)
aRefers to SAF-2.(R&D Systems Inc., Minneapolis, USA), alone or in combination, or
in the presence of IL-1 receptor antagonist (IL-1RA, 320 ng/ml,
R&D Systems), dexamethasone (2 lM, Sigma, Germany) or sodium-
butyrate (1 lM, Sigma) [19].
2.3. RNA isolation and Northern blot analysis
Total cellular RNA was isolated from JAR and Jeg-3, HUH-7,
THP-1, and ﬁrst trimester trophoblast cells, using RNeasy kit (QIA-
GEN, Vienna, Austria). Northern blots were performed as described
[17,18]. Brieﬂy, 12 lg of RNA was resolved by 1% formaldehyde–aga-
rose gel electrophoresis, transferred to a Hybond-N-nylon membrane
and UV-cross-linked. The A-SAA cDNA probe was radiolabeled with
[32P] dCTP by Prime-a-Gene Labeling System (Promega, Mannheim,
Germany), and hybridized with the membranes overnight, at 65 C,
in presence of 0.15 M sodium-phosphate, 1 mM EDTA, 7% SDS,
and 1% BSA. The hybridized blots were washed and exposed to X-
ray ﬁlm for 2–7 days.
2.4. Reverse-transcriptase-polymerase chain reaction
Reverse transcription was done with Superscript II Rnase H Re-
verse Transcriptase (Invitrogen) under the following conditions:
65 C, 5 min; 25 C, 10 min; 42 C, 90 min; 70 C, 15 min. One lg of
RNA either isolated as described above or purchased from Stratagene
(Universal human reference RNA, used as control) was transcribed
[19]. End concentrations of the components (20 ll reaction) were:
0,75 lM random hexamers, 625 nM dNTPs, 10 mM DTT, 100 U re-
verse transcriptase. All but RNA and random hexamers was added
to the reaction when reaction temperature reached 42 C. PCR was
performed with Taq polymerase (Solis Biodyne, Estonia) using 2 ll
cDNA from reverse transcription reaction as template. The ﬁnal con-
centrations in the PCR reaction mix (50 ll reaction volume) were:
100 pM of each primer, 250 ng each dNTP, 0.5 U Taq-polymerase.
The conditions of PCR reactions were as follows: Taq polymerase acti-
vation 15 min; 30 (in the case of IL-1 receptor type 1 [IL-1R1], IL-1R2,
TNFR1, SAF-1/2) or 40 cycles (in the case of SAA1, SAA2, and IL-
6R) 1 min at 95 C, 1 min at annealing temperature, 1 min at 72 C;
followed by a ﬁnal 10 min elongation at 72 C. Annealing temperature
for each primer pair is listed in Table 1. Control reactions using RNA
as template were performed in all experiments.
2.5. Immunoﬂuorescence and confocal laser scanning microscopy
JAR and Jeg-3 cells were cultured on Lab-Tek chamber slides
(Nunc, USA) in the absence or presence of 10 ng/ml IL-1b (JAR) or
TNFa (Jeg-3) up to 24 h. Then, the cells were washed with PBS, air
dried (2 h, 22 C), and acetone-ﬁxed (5 min) [21]. Fixed chamber slides
were incubated for 30 min with either sequence-speciﬁc anti-humanperature
Fragment size (bp) Annealing temperature (C)
303 53
327 55
/1353a) 190/428 59
61a)
470 58
1)
540 59
400 63
492 62
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[22] followed by 30 min incubation with cyanine-3-labeled goat anti-
rabbit IgG (dilution 1:300, Jackson Dianova) [21]. PBS was used for
washing sections between diﬀerent incubation steps. Sections were
mounted with Moviol (Calbiochem-Novabiochem, La Jolla, USA)
and analyzed on a confocal laser scanning microscope (Leica TCS
NT, Heidelberg, Germany) equipped with an argon–krypton laser. Sig-
nals were detected with a double dichroitic beam splitter (488/568 nm),
using a 590 nm long pass ﬁlter for cyanine-3. Control experiments
encompassed immunocytochemistry (i) without primary antibody,
(ii) with polyclonal non-immune antiserum as primary antibody, (iii)
without secondary antibody or (iv) with preabsorption of the corre-
sponding primary antibody with human A-SAA1 [19].
2.6. Statistics
Data are expressed as means ± S.D. with number of observations (n)
and were analyzed by ANOVA. Diﬀerences were considered signiﬁcant
at P < 0.05.3. Results
3.1. Cytokine- and glucocorticoid-mediated A-SAA induction in
choriocarcinoma cells
Northern blot experiments revealed subtle diﬀerences in A-
SAA expression between the two cell lines after 24 h (Fig. 1).
In JAR cells, highest A-SAA expression occurred after stimu-
lation with IL-1a and/or IL-1b while no additive eﬀect on
mRNA expression was found with a combination of both ago-
nists (Fig. 1). The presence of IL-1RA (known to bind to IL-
1R1) impaired A-SAA expression induced by either IL-1a or
IL-1b, two polypeptides that have limited sequence similarity
but share similar biological properties. IL-1RA alone had no
eﬀect on the synthesis of A-SAA (data not shown). Stimulation
with TNFa resulted only in moderate A-SAA mRNA expres-
sion, while IL-6 had no eﬀect. In contrast to JAR, baseline A-
SAA mRNA levels were found in Jeg-3 even under non-stim-
ulated conditions. IL-1a, IL-1b, and the combination of both
agonists only moderately enhanced A-SAA expression that
was reduced by addition of IL-1RA (Fig. 1). The mostFig. 1. Northern blot analysis of cytokine-mediated A-SAA induction
in choriocarcinoma cells. Cells were stimulated with individual
agonists (10 ng/ml) or combinations in the absence or presence of
IL-1RA (320 ng/ml). Northern blot experiments were performed using
a speciﬁc A-SAA cDNA as a probe. As expression of most genes
commonly used for normalization are also cytokine-responsive, the
28S rRNA was used as gel loading control. Note that detection of A-
SAA in Jeg-3 cells was at 3-fold longer exposure time versus JAR cells.
One representative experiment out of three is shown.pronounced A-SAA induction in Jeg-3 was found with TNFa
while IL-6 did not signiﬁcantly increase A-SAA mRNA
expression compared to non-stimulated conditions.
Treatment of choriocarcinoma cells with dexamethasone (a
synthetic glucocorticoid) and butyrate (a short-chain fatty acid
produced by bacterial fermentation in the mammalian colon
that may inhibit cell proliferation) resulted in a diﬀerent re-
sponse of A-SAA mRNA expression. Both compounds failed
to stimulate A-SAA in JAR cells, although dexamethasone
in combination with IL-1a/b had synergistic eﬀect on A-SAA
mRNA expression; further addition of butyrate antagonized
A-SAA expression (data not shown). In Jeg-3 dexamethasone
alone induced A-SAA production to levels achieved with IL-1
alone. Butyrate had no eﬀect in combination with cytokines
used (data not shown).
As IL-1b and TNFa are potent stimuli for A-SAA mRNA
expression in JAR and Jeg-3, respectively (Fig. 1), time- and
cytokine concentration-dependent expression of A-SAA was
investigated. Densitometric evaluation of Northern blot experi-
ments revealed that A-SAA expression in JAR cells increased
signiﬁcantly in a time- and IL-1b concentration-dependentman-
ner (Fig. 2). A similar observation was made for Jeg-3 using
TNFa as an agonist; signiﬁcant diﬀerences (P < 0.0001) in
SAAmRNA expression compared to baseline levels were found
at 1.0 and 10 ng TNFa.Fig. 2. Time- and concentration-dependent transcription of A-SAA in
choriocarcinoma cells. JAR and Jeg-3 cells were stimulated with 0, 0.1,
1.0, and 10 ng/ml of IL-1b (JAR) or TNFa (Jeg-3) at indicated time
periods and Northern blot experiments were performed using a speciﬁc
A-SAA cDNA. The 28S rRNA was used as gel loading control. Values
of densitometric evaluation represent means ± SD from one represen-
tative experiment (of three) performed in triplicates.
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choriocarcinoma cells
Because of the high sequence similarity between SAA1 and
SAA2 [2], the cDNA used in Northern blot experiments did
not diﬀerentiate between both A-SAA isoforms. Therefore,
an RT-PCR using speciﬁc primer pairs (Table 1) was per-
formed. Fig. 3 shows that after cytokine-treatment SAA1
and SAA2 transcripts are present in JAR and Jeg-3 cells.
SAA1 is predominantly expressed while SAA2 expression is
lower, ﬁndings in line with observations that SAA1 is the pre-
dominant A-SAA protein expressed under inﬂammatory con-
ditions [1,2]. As already shown by Northern blot analysis
(Fig. 1), SAA1 was detectable in JAR cells after treatment with
all cytokines except IL-6; furthermore, SAA1 was barely
detectable in non-stimulated cells (Fig. 3). In Jeg-3, pro-
nounced SAA1 expression was observed by TNFa. A weaker
intensity of SAA1 was found with other agonists (Fig. 3).
Next we tested whether the human homologue of SAF-1/2 is
also expressed in choriocarcinoma cells. The primer pair used
recognizes both SAF transcripts. Human SAF-1 is present in
JAR (Fig. 4) and Jeg-3 (data not shown) even under non-stim-
ulated conditions while SAF-2 (a splice variant of SAF-1) was
undetectable in choriocarcinoma cells cultured in the absence
or presence of cytokines.Fig. 3. RT-PCR for SAA1/2 in choriocarcinoma cells. Cells were
stimulated with individual agonists (10 ng/ml) or combinations in the
absence or presence of IL-1RA (320 ng/ml). The cDNA for SAA1 and
SAA2 was ampliﬁed using speciﬁc forward and reverse oligonucleotide
primers (Table 1). The PCR product was separated on a 2% agarose
gel. P (positive control, HUH-7); N1 (negative control, RNA template:
negative controls were done for all samples); N2 (negative control,
water template); Std (bp standard). One representative experiment out
of three is shown.
Fig. 4. RT-PCR of SAF-1/2- transcripts in choriocarcinoma cells. JAR
cells were stimulated with individual agonists (10 ng/ml) or combina-
tions in the absence or presence of IL-1RA (320 ng/ml) and RNA was
isolated. The cDNA for the human SAF homolog was ampliﬁed using
speciﬁc forward and reverse oligonucleotide primers (Table 1). The
PCR product was separated on a 2% agarose gel. P (positive control,
reference RNA from Stratagene); N1 (negative control, RNA template:
negative controls were done for all samples); Std (bp standard). One
representative experiment out of three is shown.Thenwe studied expression ofA-SAA- andSAF-transcripts in
in utero invasive cells. To mimick in vivo conditions, RNA was
isolated from diﬀerent ﬁrst trimester trophoblast cell prepara-
tions that have not been stimulated ex vivo by cytokines. While
expression of SAA1 and SAA2 is low during early placental
development (weeks 7–9) expression rates are signiﬁcantly in-
creased after pregnancy week 9 (Fig. 5). The human analog of
SAF-1 is also present in ﬁrst trimester trophoblast cells
(Fig. 5); these data parallel observations of SAF-1 expression
in choriocarcinoma cells even under non-stimulated conditions
(Fig. 4, lane 7). In line with ﬁndings of SAA induction, SAF-1
expression parallels expression ofSAA1 andSAA2 in pregnancy
weeks 10 and 12. SAF-2 expression could not be veriﬁed in ﬁrst
trimester trophoblast preparations (Fig. 5).Fig. 5. RT-PCR for SAA1/2- and SAF-1/2-transcripts in human
trophoblast cells. RNAwas isolated from diﬀerent ﬁrst trimester human
trophoblast cell preparations (pregnancy weeks 7–12), reverse tran-
scribed, and cDNA for human SAA1, SAA2, SAF-1, and SAF-2 was
ampliﬁed using speciﬁc forward and reverse oligonucleotide primers
(Table 1). The PCR product was separated on a 2% agarose gel. P
(positive control, HUH-7); N1 (negative control, RNA template:
negative controls were done for all samples). To ensure that equal
amount of cDNA was used as a template RT-PCR for GAPDH was
made as a control. One representative experiment out of three is shown.
Fig. 6. RT-PCR of cytokine receptors on choriocarcinoma cells. RNA
was isolated from JAR, Jeg-3, HUH-7, and THP-1 cells, reverse
transcribed, and cDNA for human IL-1R1, IL-1R2, TNFR1, and IL-
6R was ampliﬁed using speciﬁc forward and reverse oligonucleotide
primers (Table 1). The PCR product was separated on a 2% agarose
gel. N1 (negative control, RNA template: negative controls were done
for all samples); Std (bp standard). One representative experiment out
of three is shown.
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induction in choriocarcinoma cells
To check for the presence of cytokine receptors on chorio-
carcinoma cells, an RT-PCR analysis was performed. Human
hepatoma cells (HUH-7) or mononucleated phagocytes (THP-
1) – known to express cytokine receptors [23] and to synthetise
A-SAA [19,20] – served as controls. Both JAR and Jeg-3 ex-
press IL-1 and TNFa receptors (Fig. 6), responsible for bind-
ing and transducing the actions of corresponding cytokines.
Additionally, both cell lines express IL-1R2, a decoy receptor
that binds IL-1 but is unable to start a signaling cascade.
The IL-6 receptor was found in JAR but not in Jeg-3.
3.4. Immunocytochemical staining for SAA in choriocarcinoma
cells
The presence of A-SAA protein was conﬁrmed by immuno-
cytochemistry. In non-stimulated JAR cells no staining for
A-SAA was present (Fig. 7A), while after a 4 h stimulation
(IL-1b) faint staining became apparent in the cell membrane
and the Golgi apparatus (Fig. 7B). After a 12 h stimulation
most cells showed strong positivity in the Golgi, although
not all cells did express A-SAA (Fig. 7C). After 24 h stimula-
tion, pronounced positivity for SAA1/2 was observed althoughFig. 7. Immunocytochemical evidence for A-SAA protein on choriocarcinom
as described in Section 2. Labeling was performed with anti-human SAA1/2
anti-rabbit IgG. A (control, 0 h); B (4 h); C (12 h), D (24 h). One representati
ﬁeld is 240 lm.staining intensity appeared more diﬀuse (Fig. 7D). Identical
staining patterns for SAA1/2 were observed when Jeg-3 cells
were stimulated with TNFa under identical experimental con-
ditions (data not shown). Expression levels of SAF-1 protein
were too low to be detected by immunocytochemistry under
the conditions described.4. Discussion
A-SAA levels are increased not only during inﬂammatory
conditions but also in a broad spectrum of neoplastic diseases
[24] that may predispose to amyloidosis [25]. A number of
studies proposed a direct correlation between A-SAA concen-
trations and tumor grading [26]. This led to the assumption
that A-SAA might be considered a marker to monitor tumor
progression and even a biomarker for speciﬁc cancer types
[27]. However, there is still debate whether SAA is synthesized
directly by neoplastic cells or is released into the circulation by
the liver. In human hepatocellular carcinoma cell lines, A-SAA
has been found to be a direct tumor cell product after cyto-
kine-mediated induction [28]. Also colonic adenocarcinoma
and cell lines derived therefrom are cytokine-responsive to givea cells. JAR cells were cultured up to 24 h on Lab-Tek chamber slides
antibodies followed by 30 min incubation with cyanine-3-labeled goat
ve experiment out of three is shown. The x/v dimension of the scanned
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that expression of A-SAA by cytokines alone and/or in combi-
nation as well as glucocorticoid enhancement of the cytokine-
driven transcriptional activation may diﬀer [30,31]. Glucocor-
ticoids have immunosuppressive and antiinﬂammatory ac-
tions, e.g., downregulated expression of pro-inﬂammatory
cytokines and are used in the treatment of many rheumatic
and other inﬂammatory diseases. Paradoxically, glucocorti-
coids augment the expression of A-SAA in hepatocellular car-
cinoma [32] by mechanisms that involve transcriptional
activation by IL-1 and IL-6 [33,34]. We here observed that
in both choriocarcinoma cell lines dexamethasone contributes
to A-SAA expression. On the other hand, SAF-1 has been
shown to regulate non-hepatic expression of SAA under
inﬂammatory conditions. SAF-1 is also present in choriocarci-
noma cells (Fig. 4) and ﬁrst trimester trophoblast (Fig. 5).
Observations that expression of SAF-1 parallels expression
of A-SAA in ﬁrst trimester trophoblast suggest this transcrip-
tion factor to act as a likely upstream activator of A-SAA
[33,34]. SAF-2, a negative regulator of inﬂammation [34], is
probably expressed in adult tissues [34], but could not be de-
tected in tissue of fetal origin (Fig. 4).
As cytokines are important components of a paracrine/
autocrine communication network operating within the
feto-maternal interface [8] and no summarized data on the
expression of cytokine receptors on choriocarcinoma cells ex-
ist, we checked for the expression of IL-1, TNFa and IL-6
receptors on JAR and Jeg-3 cells. The presence of IL-1R
and IL-1R2 on choriocarcinoma cells suggests the important
role of IL-1 in balancing the signal transduction pathways in
trophoblast-(like) cells. The expression of TNFR1 transcripts
in JAR and Jeg-3 cells (Fig. 6) is in agreement with in situ
hybridisation data, where low mRNA levels were detected
in early villous cytotrophoblast [35]. However, the low
responsiveness of JAR towards TNFa may not be explained
by the high expression of TNFR1 but is a likely consequence
of altered intracellular signaling events. In contrary, the ab-
sence of IL-6R in JAR explains the lack of A-SAA induction
in these cells after IL-6 stimulation.
During inﬂammation, A-SAA seems to exhibit Janus-faced
eﬀects. While Shainkin-Kestenbaum et al. [36] addressed a
feedback mechanism of A-SAA on IL-1-induced inﬂammatory
events, Patel et al. [37] reported that A-SAA exerts cytokine-
like properties by inducing release of IL-1 in THP-1 cells.
However, the role of A-SAA in fetal tissue and fetal/placental
development remains unknown. A likely function of A-SAA in
trophoblast and trophoblast-like cells is its role in lipid metab-
olism. The uptake of esteriﬁed cholesterol from high-density
lipoproteins occurs primarily via SR-BI, a scavenger recep-
tor-class B, type I, expressed on the feto-maternal interface
and necessary for embryonic development [38]. SR-BI is abun-
dantly expressed in JAR and Jeg-3 [17] and in rapidly growing
ﬁrst trimester trophoblast cells [18] leading to increased prolif-
eration and cellular growth [17,18]. However, during inﬂam-
matory conditions occurring in vivo and in vitro SR-BI is
downregulated [39,40] while A-SAA is highly upregulated.
Both free and acute-phase high-density lipoproteins-associated
A-SAA acts as a preferential ligand for SR-BI [41] by impair-
ing binding of and selective cholesteryl ester uptake from lipo-
proteins of the high-density range. As a consequence
cholesterol/cholesteryl ester-supply to the growing embryo is
defective which may result in impaired cell growth and intra-uterine growth retardation during inﬂammatory events, e.g.,
preeclampsia.
Summarizing we could show that in utero invasive ﬁrst tri-
mester trophoblast and malignant trophoblast-like choriocar-
cinoma cells – both representing placental-derived cells of
fetal origin – express A-SAA transcripts. Whether A-SAA
has a protective role in fetal tissues contributing to the mainte-
nance of cytokine balance or could adversely aﬀect fetal
growth under imbalanced cytokine conditions, remains to be
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